Christopher Drinjak

Christopher specialises in assisting lawyers to enhance their skills, win new instructions, manage client relationships and augment their international networks.

He has worked in senior business development roles based in the UK and in Germany, and currently is the business development lead for the firm's Life Sciences & Healthcare industry sector.

CV

Since 2019 Senior business development manager (Life sciences and healthcare), and Senior business development manager (Disputes and investigations, IP, Commercial tech and data, and Patents), Taylor Wessing

2011 - 2018 Senior practice development manager, Industry development (Global financial institutions group), and Interim head of business development Germany, Latham & Watkins

2001 - 2011 Business development manager (Finance and capital markets), Head of London L&DR business development, and Business development manager (Litigation and dispute resolution), Clifford Chance

Carrière

2011 - 2018 Senior practice development manager, Industry development (Global financial institutions group), and Interim head of business development Germany, Latham & Watkins

2001 - 2011 Business development manager (Finance and capital markets), Head of London L&DR business development, and Business development manager (Litigation and dispute resolution), Clifford Chance

Formation

2001 Masters of business administration, International University, Germany

1996 M.A. in musicology, Michigan State University, US

1994 B.A. in German and B.A. in Music Performance, Michigan State University, US

Christopher Drinjak

Expertise

Secteurs

CV

Carrière

Formation

Langues étrangères

Christopher Drinjak

Expertise

Secteurs

CV

Carrière

Formation

Langues étrangères

Related news & insights

Oli Denne recognised in The Lawyer's Hot 100 2026

Research and innovation as a competitive advantage – Legal framework for Life Sciences made in Europe

Life Sciences Made in Europe – The European Commission’s Life Sciences Strategy 2030

Adoption of Commission Implementing Regulation (EU) 2025/2086: New Rules on the Joint Clinical Assessment of Medical Devices and In Vitro Diagnostic Medical Devices

EU Inc.: Founders and companies with expansion plans must now think strategically

Advising Nuclera on its extended Series C funding to US$87 million

Word on the street at the J.P. Morgan Healthcare Conference 2026: Part one

Word on the street at the J.P. Morgan Healthcare Conference 2026: Part two

Update from Berlin: Federal government tightens cannabis policy

Partner appointment Margot van Gerwen

Autres avocats qui pourraient vous intéresser

Rendez-vous à